Month: February 2021

February 26, 2021Dear Shareholders and Investors, Highlights: The following main elements in our business stand out at this time:During 2020 we distributed $67.2 million in cash dividends and repaid our existing loans with a gross amount of $75.5 million.The first half of 2020 was a strong period for NATThe third quarter of 2020 came out positively with a timecharter equivalent of about $25,000 per day per shipThe fourth quarter of 2020 was weakWe undertook planned technical maintenance of our ships during softer market periods of 2020 At the time of this report the market has improved and we believe that we are close to a significant positive turnaroundThe full year 2020 produced a net income of $50 million or an earning per share (EPS) of $0.34. This is an improvement of about $60 million in 2020 compared to 2019, which produced an...

On February 26, 2021 AB “Linas” Board confirmed AB “Linas” consolidated interim financial reports of twelve months of year 2020 which are not checked by the auditors and prepared acc.to International financial accountability standards accepted by EU.The sales incomes for January-December of year 2020 of AB “Linas” Group of companies made 14.01 mill. EUR. During the same period of year 2019 sales incomes were 12.98 mill. EUR.Profit before taxation of the twelve months of year 2020 of AB “Linas” group of companies – 0.62 mill. EUR. Group result for same period of year 2019 – 0.13 mill. EUR profit.Presenting confirmation of the responsible persons of AB “Linas” and interim consolidated not audited financial information of twelve months of year 2020.AB “Linas” chief of financeEgidijus Mikeliūnas+370 45 506100AttachmentTarpinė konsoliduota...

2021 m. vasario 26 d. AB „Linas“ valdyba patvirtino auditorių netikrintas AB „Linas“ 2020 metų dvylikos mėnesių konsoliduotas tarpines finansines ataskaitas, parengtas pagal ES priimtus Tarptautinius finansinės atskaitomybės standartus.AB „Linas“ Grupės 2020 metų sausio-gruodžio mėnesių pardavimo pajamos sudarė 14,01 mln. eurų, kai 2019 m. tuo pačiu laikotarpiu – 12,98 mln. eurų.AB „Linas“ įmonių grupės 2020 metų dvylikos mėnesių pelnas prieš apmokestinimą – 0,62 mln. eurų. 2019 m. to paties laikotarpio Grupės rezultatas – pelnas 0,13 mln. eurų.Pateikiame AB „Linas“ atsakingų asmenų patvirtinimą ir 2020 m. dvylikos  mėnesių tarpines konsoliduotas neaudituotas finansines ataskaitas.AB „Linas“ finansų vadovasEgidijus Mikeliūnas+370 45 506100PriedasTarpinė konsoliduota atskaitomybė už 2020 4ketv. LTU

COPENHAGEN, Denmark, Feb. 26, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the launch of Outgrow GHD, a new online educational resource designed to help caregivers of children with growth hormone deficiency (GHD) in the United States (U.S.) navigate their personal GHD journeys.“We are excited to announce Outgrow GHD to support children with GHD and their families as they manage their lives with this rare endocrine disease. The resource is a place where caregivers of children with this rare disease can learn from and inspire each other,” said Ami Knoefler, Senior Director, Patient Advocacy and Product Communications at Ascendis Pharma. “Outgrow GHD reflects our commitment to improve awareness...

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 26, 2021 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:Cowen 41stAnnual Health Care Conference, March 1 – 4, 2021Members of uniQure’s management team including Matt Kapusta, chief executive officer, and Ricardo Dolmetsch, Ph.D., president of research & development, will participate in virtual one-on-one investor meetings throughout the day on Monday, March 1.David Cooper, M.D., vice president of clinical research CNS, will participate on a panel discussion entitled “Developing and Commercializing Neurological Therapies” on Thursday, March 4 at 1:30 p.m. ET....

Vincit OyjYhtiötiedote 26.2.2021 kello 14:00Vincit Oyj:n toimintakertomus ja tilinpäätös vuodelta 2020 julkaistuVincit Oyj on julkaissut hallituksen toimintakertomuksen ja tilinpäätöksen vuodelta 2020.Hallituksen toimintakertomus ja tilinpäätös 2020 on saatavilla PDF-muotoisena tämän tiedotteen liitteenä sekä yhtiön verkkosivuilta osoitteessa http://www.vincit.fi/fi/sijoittajille/raportit-ja-esitykset/.Lisätietoja:Vincit Oyj, toimitusjohtaja Mikko Kuitunen, puhelin: 040 589 8316Hyväksytty neuvonantaja: Alexander Corporate Finance Oy, puhelin: 050 520 4098Vincit Oyj lyhyesti:Vincit on huippuasiantuntijaorganisaatio, joka tarjoaa asiakkailleen aina toimivinta digitaalisuutta ymmärrettävässä paketissa, jotta huominen ei pelota. Vincit Oyj:n osakkeet on listattu Nasdaq Helsinki Oy:n ylläpitämällä Nasdaq First North Growth Market Finland -markkinapaikalla,...

YTD Q4 2020, the Jotul Group reached a consolidated profit of MNOK -128.9 (Q4 2019: MNOK -86.8). The operating result totaled MNOK -66.7 in YTD Q4 2020 (Q4 2019: MNOK 27.3). The 2020 total comprehensive loss for YTD Q4 was MNOK -127.5 (Q4 2019: MNOK     – 85.7).Sales for the period declined by 6.1% to MNOK 905.5 YTD Q4 2020 (Q4 2019 MNOK 961,1), which is less than initially anticipated at the outbreak of the COVID-19 pandemic. The fourth quarter continued to show a strong recovery in order intake, up from MNOK 269 in Q4 2019 to MNOK 305 in Q4 2020. Total order book as per Q4 2020 was MNOK 122 (Q4 2019 MNOK 29). In addition to the strong recovery in the market during the second half of 2020, the large backlog as per Q4 2020 is also related to the limited output capacity at the new production facility in Poland during the pandemic.In...

Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated DiseasesSilence to receive $2 million research milestone paymentSilence is also eligible to receive up to $2 billion in total milestone payments across all three targets and tiered double-digit royalties on net sales for each product candidate26 February 2021LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the Company will receive a $2.0 million milestone payment following the initiation of work on a third target being explored under its ongoing RNAi research collaboration...

New York, NY, Feb. 26, 2021 (GLOBE NEWSWIRE) — George Goldsmith, Chairman & CEO, to participate in Neuropsych Panel discussion London, UK – 26 February 2021-Ends-About COMPASS PathwaysCOMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently...

CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2020 financial results will be released on Thursday, March 4, 2021 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.Dial-in NumberU.S./Canada Dial-in Number: 800-527-6973International Dial-in Number: 470-495-9162Conference ID: 6376419Replay Dial-in Number: 855-859-2056Replay International Dial-in Number: 404-537-3406Conference ID: 6376419An audio webcast will be accessible through the Investor Relations section of the company’s...